Safety of Infliximab in Inflammatory Bowel Disease Needs to Be Debated
, 29 December 2008
Hilbert S. de Vries, Martijn G.H. Van Oijen, Dirk J. de Jong
Clinical Gastroenterology and Hepatology
May 2009 (Vol. 7, Issue 5, Pages 603-604) Full Text |
Full-Text PDF (150 KB)
The following reply refers to a letter to the editor (de Vries HE, Van Oijen MGH, de Jong DJ. Safety of infliximab in inflammatory bowel disease needs to be debated. Clin Gastroenterol Hepatol 2009;7:603–604) published in the May 2009 issue of Clinical Gastroenterology and Hepatology.
⁎Department of Medical Gastroenterology, University of Copenhagen, Herlev, Denmark
‡Department of Medical Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark
§Institute of Preventive Medicine, Copenhagen University Hospital, Copenhagen, Denmark
Conflicts of interest The authors disclose the following: Dr Caspersen has received travel grants and payment for oral presentations from Schering-Plough, Denmark. Dr Bendtsen is a member of an advisory board for Schering-Plough, Denmark. The remaining authors disclose no conflicts.
PREVIEW